Publications by authors named "Massimo Maffezzini"

Claim this Profile
[
[Not Available].
Pasquale Paletta, Paola Mosconi, Cinzia Colombo, Enza Dossena, Fabrizio Longo, Massimo Maffezzini

Recenti Prog Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repositioning of antiarrhythmics for prostate cancer treatment: a novel strategy to reprogram cancer-associated fibroblasts towards a tumor-suppressive phenotype.
Valentina Doldi, Monica Tortoreto, Maurizio Colecchia, Massimo Maffezzini, Stefano Percio

J Exp Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extraperitoneal cystectomy with ureterocutaneostomy derivation in fragile patients - should it be performed more often?
Rafaela Malinaric, Guglielmo Mantica, Federica Balzarini, Carlo Terrone, Massimo Maffezzini

Arch Ital Urol Androl· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62.
Claudia Signorini, Massimo Maffezzini

Eur Urol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients.
Massimo Maffezzini, Vincenzo Fontana, Andrea Pacchetti, Federico Dotta, Mattia Cerasuolo

Arch Ital Urol Androl· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing a five-step training model for transperineal prostate biopsies in a naïve residents' group: a prospective observational randomised study of two different techniques.
Guglielmo Mantica, Andrea Pacchetti, Roberta Aimar, Mattia Cerasuolo, Federico Dotta, Massimo Maffezzini

World J Urol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dermal graft surgery for Peyronie's disease: Long term results at a 15 years follow-up.
Aldo Franco De Rose, Guglielmo Mantica, Massimo Maffezzini, Carlo Terrone

Arch Esp Urol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pathologist's role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detection.
Guglielmo Mantica, Alchiede Simonato, Danelo E Du Plessis, Massimo Maffezzini, Aldo F De Rose

Minerva Urol Nefrol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large bladder diverticula: a comparison between laparoscopic excision and endoscopic fulguration.
Mauro Pacella, Guglielmo Mantica, Massimo Maffezzini, Matteo Justich, Paolo Traverso

Scand J Urol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eleven-year management of prostate cancer patients on active surveillance: what have we learned?
Cristina Marenghi, Maria Francesca Alvisi, Federica Palorini, Barbara Avuzzi, Fabio Badenchini, Massimo Maffezzini

Tumori· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"What if…": decisional regret in patients who discontinued active surveillance.
Claudia Repetto, Tiziana Rancati, Tiziana Magnani, Maria Francesca Alvisi, Barbara Avuzzi, Massimo Maffezzini

Tumori· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Tom J H Arends, Ofer Nativ, Massimo Maffezzini, Ottavio de Cobelli, Giorgio Canepa

Eur Urol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation.
Valentina Doldi, Maurizio Callari, Elisa Giannoni, Francesca D'Aiuto, Massimo Maffezzini

Oncotarget· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
Andrea Necchi, Elena Farè, Salvatore Lo Vullo, Patrizia Giannatempo, Daniele Raggi, Massimo Maffezzini

Clin Genitourin Cancer· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Daniele Raggi, Luigi Mariani, Patrizia Giannatempo, Salvatore Lo Vullo, Daniele Giardiello, Massimo Maffezzini

Urol Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Focal therapy in urology: kidney cancer].
Alessandro Crestani, Carlo Spreafico, Massimo Maffezzini, Roberto Salvioni

Urologia· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy.
Andrea Necchi, Patrizia Giannatempo, Biagio Paolini, Salvatore Lo Vullo, Manuela Marongiu, Massimo Maffezzini

Clin Genitourin Cancer· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design.
Andrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, Elena Farè, Daniele Raggi, Massimo Maffezzini

Clin Genitourin Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center.
Andrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, Elena Farè, Daniele Raggi, Massimo Maffezzini

Clin Genitourin Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease.
Nicola Nicolai, Andrea Necchi, Daniele Raggi, Davide Biasoni, Mario Catanzaro, Massimo Maffezzini

Urology· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
Patrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, Daniele Raggi, Elena Farè, Massimo Maffezzini

Clin Genitourin Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
Michele Lodde, Christine Mian, Roman Mayr, Evi Comploj, Emanuela Trenti, Massimo Maffezzini

Int J Urol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to editorial comment from Dr Todenhöfer and Dr Schwentner to recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
Michele Lodde, Christine Mian, Roman Mayr, Evi Comploj, Emanuela Trenti, Massimo Maffezzini

Int J Urol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Andrea Necchi, Luigi Mariani, Patrizia Giannatempo, Daniele Raggi, Elena Farè, Massimo Maffezzini

Clin Genitourin Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.
Massimo Maffezzini, Fabio Campodonico, Giorgio Canepa, Egi Edward Manuputty, Stefania Tamagno

Cancer Chemother Pharmacol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis